What You Should Know About The Future of the U.S. Drug Enforcement Administration

The Drug Enforcement Agency has a new leader: Donald Trump.

The agency’s new chief, John DeLong, has made an early splash with his hardline views on drugs, arguing that legalizing marijuana could reduce the violence and violence in communities, as well as the deaths of police officers.

The Trump administration is expected to announce a new drug czar soon.

But in the meantime, DeLong has already taken on the mantle of drug czars.

In March, DeBlasio was named the first woman to lead the DEA.

“We are not going to see a big change, but a big shift,” DeBlasi said.

“It is not going away.”

DeBlasio has a long history with the DEA and was an outspoken critic of the agency during her tenure as head of the Justice Department’s civil rights division under former President Bill Clinton.

The DEA’s current chief, Michele Leonhart, has a far less liberal record than DeBlacio, a former prosecutor and U.N. ambassador.

DeBlasi’s nomination to lead drug czas bureau will likely be confirmed by the Senate.

He will replace David Abrams, who left the DEA in October and was appointed deputy attorney general in May.

The Senate Judiciary Committee will hold a hearing on DeBlas nomination on Monday.

The drug czares bureau will oversee an overhaul of the DEA, which has been criticized for years for being overly punitive toward small-time drug users.

Last year, the DEA approved a new schedule 1 drug, OxyContin, for sale on the street, but its use has increased.

Critics say the DEA’s excessive force policy is contributing to the rise of opioid abuse.

The Trump administration has been working to reform the agency.